Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients
The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment
Incyte got approval from Europe to sell a skin-cream medicine for adults with a serious itchy skin condition. This is good news because it means more patients can use the treatment, which helps the company grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.